Important Notice: Authorization Changes

04/16/2019

Dear Valued Provider:

According to our contractual agreement, Cigna-HealthSpring is required to provide you with notice of any material changes in our policies and procedures. This letter and the enclosed attachment serve as notice of a change to Authorization Requirements which will be effective 06/01/2019. This adjustment has been made to the 2019 STAR+PLUS Provider Manual and the corrected document has been placed online at http://starplus.cignahealthspring.com for your review and reference.

If you have any questions regarding this letter or the enclosed attachment, please contact Provider Services at 1-877-653-0331.

Sincerely,

Patricia English
Patricia English, RN, CCM
Director, Utilization Management

Enclosures: Please see the comparison chart, which references the changes and updates made to Authorization Requirements.
### Comparison Chart

<table>
<thead>
<tr>
<th>Authorization Additions</th>
<th>Authorizations Removed from Requirements - Medical</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1300 Eculizumab, 10 mg</td>
<td>Oxygen</td>
</tr>
<tr>
<td>J9354 Ado-Trastuzumab Emtansine</td>
<td>Ambulatory Blood Pressure Monitoring</td>
</tr>
<tr>
<td>C9484 eteplirsen Exondys 51</td>
<td>Sleep studies</td>
</tr>
<tr>
<td>C9489 nusinersen, Spinraza</td>
<td>Enhanced External Counterpulsation (EECP)</td>
</tr>
<tr>
<td>Q2040 Tisagenlecleucel , Kymriah</td>
<td>Hernia Repairs</td>
</tr>
<tr>
<td>C9014,cerliponase alfa, Brineura</td>
<td>Vagus Nerve Stimulations</td>
</tr>
<tr>
<td>C2098, inotuzumab ozogamicin , Besponsa</td>
<td>Wound care-outpatient setting</td>
</tr>
<tr>
<td>Q2041, axicabtagene ciloleucel, Yescarta</td>
<td>Podiatry</td>
</tr>
<tr>
<td></td>
<td>TMJ</td>
</tr>
<tr>
<td></td>
<td>Cardiac Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Oral Surgery</td>
</tr>
</tbody>
</table>

#### New Lab Codes Providers Can Perform in Office

#### Authorizations Removed from Requirements - Behavioral Health

- Outpatient Psychological and Neuropsychological testing
- Neurobehavioral Assessment
- Outpatient Electroconvulsive Therapy (ECT)
- Residential Detox
- Mental Health Rehabilitation
- Targeted Case Management

#### In Office Labs Removed from requirements

- 81007 Urinalysis; bacteriuria screen, except by culture or dipstick
- 84520 Urea nitrogen; quantitative
- 83026 Hemoglobin; by copper sulfate method, non-automated
- 84478 Triglycerides

#### New Lab Codes Providers Can Perform in their Office without sending to an Outside Lab

- 81000 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy
- 81015 Urinalysis; microscopic only
- 82043 Albumin; urine (eg, microalbumin), quantitative
- 82247 Bilirubin; total
- 82271 Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources
- 82465 Cholesterol, serum or whole blood, total
- 82565 Creatinine; blood
- 82948 Glucose; blood, reagent strip
- 82950 Glucose; post glucose dose (includes glucose)
- 82951 Glucose; tolerance test (GTT), 3 specimens (includes glucose)
- 82952 Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)
- 83037 Hemoglobin; glycosylated (A1C) by device cleared by FDA for home use
- 83655 Lead
- 84132 Potassium; serum, plasma or whole blood
- 85025 Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count
- 87807 Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)